Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To determine the recommended Phase IIa dose (RP2D) of the triplet combination. To determine the safety and efficacy of the combination at the RP2D.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony histopatologicznie czerniak stopnia III lub IV, który nie może być usunięty chirurgicznie
- •Co najmniej jeden, dotąd nieleczony guz, który można zmierzyć na badaniach obrazowych
- •Dostępna próbka tkanki guza do badań genetycznych
- •Nigdy wcześniej nie otrzymywali chemioterapii systemowej ani immunoterapii na czerniaką
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 28, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
The University of Texas M. D. Anderson Cancer Center
Houston, United States
Trial contact
Hussein Tawbi, MD,PHD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/28/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.